India's Symbiotec Pharmalab profit falls 53% in Q1
Shares of Symbiotec Pharmalab declined 3.11% to 1,120.10 rupees after the company reported a 53% drop in its first-quarter net profit to 141.56 million rupees ($1.48 million) compared to the previous year. Revenue from operations rose to 2.18 billion rupees from 2.03 billion rupees. Analysts at ICICI Direct Research cited expenses from new businesses as the main drag on EBITDA.
Shares of Symbiotec Pharmalab fell 3.11% to 1,120.10 rupees after the company reported its first results since its IPO. The stock could end a run of three straight sessions of gains. The company posted a 53% drop in quarterly net profit to 141.56 million rupees ($1.48 million). Revenue from operations for Q1 rose to 2.18 billion rupees from 2.03 billion rupees in the year-ago period.
Analysts at ICICI Direct Research said EBITDA was weighed by costs from new businesses that have yet to generate significant traction. The shares have gained 13.4% since their trading debut on September 1. $1 = 95.8100 Indian rupees (Reporting by Saikeerthi in Bengaluru) ((Saikeerthi@thomsonreuters.com; (+91) 8296756080)